- Home
- SYBX vs BCTX Comparison
SYBX vs BCTX Comparison
Compare SYBX & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- BCTX
- Stock Information
- Founded
- SYBX N/A
- BCTX 2014
- Country
- SYBX United States
- BCTX Canada
- Employees
- SYBX N/A
- BCTX N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- BCTX Biotechnology: Pharmaceutical Preparations
- Sector
- SYBX Health Care
- BCTX Health Care
- Exchange
- SYBX Nasdaq
- BCTX Nasdaq
- Market Cap
- SYBX 13.9M
- BCTX 13.7M
- IPO Year
- SYBX N/A
- BCTX N/A
- Fundamental
- Price
- SYBX $1.48
- BCTX $0.74
- Analyst Decision
- SYBX
- BCTX Strong Buy
- Analyst Count
- SYBX 0
- BCTX 1
- Target Price
- SYBX N/A
- BCTX $32.00
- AVG Volume (30 Days)
- SYBX 96.1K
- BCTX 2.5M
- Earning Date
- SYBX 08-15-2025
- BCTX 06-16-2025
- Dividend Yield
- SYBX N/A
- BCTX N/A
- EPS Growth
- SYBX N/A
- BCTX N/A
- EPS
- SYBX 0.21
- BCTX N/A
- Revenue
- SYBX N/A
- BCTX N/A
- Revenue This Year
- SYBX N/A
- BCTX N/A
- Revenue Next Year
- SYBX N/A
- BCTX N/A
- P/E Ratio
- SYBX $7.06
- BCTX N/A
- Revenue Growth
- SYBX N/A
- BCTX N/A
- 52 Week Low
- SYBX $0.90
- BCTX $0.69
- 52 Week High
- SYBX $1.96
- BCTX $29.40
- Technical
- Relative Strength Index (RSI)
- SYBX 52.72
- BCTX 15.11
- Support Level
- SYBX $1.53
- BCTX $0.69
- Resistance Level
- SYBX $1.96
- BCTX $0.82
- Average True Range (ATR)
- SYBX 0.19
- BCTX 0.13
- MACD
- SYBX -0.01
- BCTX 0.03
- Stochastic Oscillator
- SYBX 36.84
- BCTX 4.06
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.